48 completed. 48 Phase 3, 10 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 48 | Completed 48 |
| Phase 2 | 10 | Completed 10 |
Follow Type 1 Diabetes: new trials by email Literature Review of Type 1 Diabetes trials Research Report on Type 1 Diabetes
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Automated Insulin Delivery for Inpatients With Dysglycemia AID system with Remote Real-Time CGM, Standard of Care Insulin Therapy + CGM - Type 1 Diabetes, Type 2 Diabetes | Phase 3 | Completed | Emory University | 130 | 2025-01-22 | 2025-11-14 |
| SGLT2 Adjunct in T1D Empagliflozin (EMPA), Placebo - Type 1 Diabetes, Nephropathy, Diabetic | Phase 2 / Phase 3 | Completed | Ain Shams University | 86 | 2024-11-20 | 2026-05-18 |
| A Study to Inv. Safety, Efficacy & PD of Dasiglucagon as Hypoglycemia Rescue Therapy in Children <6 Years With T1D Dasiglucagon - Hypoglycemia, Type 1 Diabetes | Phase 3 | Completed | Zealand Pharma | 8 | 2023-05-09 | 2025-07-20 |
| Weekly Subcutaneous Semaglutide as Adjunct to Closed-loop Therapy in Type 1 Diabetes Care Outpatient therapy: 11 weeks of drug therapy with usual treatment + 4 weeks of closed-loop therapy - Type 1 Diabetes, Diabetes Mellitus, Type 1 | Phase 2 / Phase 3 | Completed | McGill University Health Centre/Research Institute of the McGill University Health Centre | 28 | 2022-10-02 | 2025-01-22 |
| A Study of Insulin Efsitora Alfa (LY3209590) Compared With Insulin Degludec in Participants With Type 1 Diabetes Treated With Multiple Daily Injection Therapy Insulin Efsitora Alfa, Insulin Degludec - Type 1 Diabetes, Diabetes | Phase 3 | Completed | Eli Lilly and Company | 692 | 2022-08-12 | 2025-06-24 |
| Efficacy and Safety of THDB0206 Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes THDB0206, Insulin Lispro, Insulin Glargine - Type 1 Diabetes | Phase 3 | Completed | Tonghua Dongbao Pharmaceutical Co.,Ltd | 550 | 2022-04-13 | 2025-12-15 |
| Oral Hypoglycemic Therapy for Monogenic Variant Carriers of the Joslin Medalist Study Metformin Extended Release Oral Tablet, Sitagliptin - Type 1 Diabetes, Monogenic Diabetes | Phase 2 / Phase 3 | Completed | Joslin Diabetes Center | 3 | 2021-08-26 | 2025-02-24 |
| A Study of LY2963016 Compared to Lantus® in Adult Chinese Participants With Type 1 Diabetes Mellitus LY2963016, Lantus®, Insulin Lispro - Type 1 Diabetes | Phase 3 | Completed | Eli Lilly and Company | 272 | 2018-03-23 | 2021-03-29 |
| Vitamin D and Residual Beta-Cell Function in Type 1 Diabetes Ergocalciferol, Placebo - Type 1 Diabetes | Phase 2 / Phase 3 | Completed | Benjamin U. Nwosu, MD | 48 | 2017-10-19 | 2024-07-10 |
| Targeting Inflammation With Salsalate in Type 1 Diabetes Neuropathy Salsalate, PLACEBO - Type 1 Diabetes, Peripheral Neuropathy | Phase 2 / Phase 3 | Completed | University of Michigan | 61 | 2016-10-01 | 2025-05-16 |
| Behavioral Economic Incentives to Improve Glycemic Control Among Adolescents and Young Adults Daily feedback, Financial incentive - Diabetes, Type 1 Diabetes | Phase 3 | Completed | University of Pennsylvania | 90 | 2016-01-01 | 2016-11-11 |
| The Lira Pump Trial Liraglutide, Placebo - Type 1 Diabetes | Phase 2 / Phase 3 | Completed | Hvidovre University Hospital | 44 | 2015-02-01 | 2020-02-12 |
| Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 1 Diabetes Mellitus Patients (INSTRIDE 1) Mylan's insulin glargine, Lantus® - Type 1 Diabetes | Phase 3 | Completed | Mylan Inc. | 558 | 2014-06-01 | 2022-03-03 |
| Feasibility Study of the JewelPump Version 3 JewelPump, usual insulin pump - Type 1 Diabetes | Phase 3 | Completed | Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète | 21 | 2014-06-01 | 2014-10-27 |
| Validation of the Artificial Pancreas Diabeloop Algorithm in the Hospital Insulin, Asp(B28)- - Type 1 Diabetes | Phase 2 / Phase 3 | Completed | Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète | 17 | 2014-05-01 | 2015-07-30 |
| Equivalence of A Stable Liquid Glucagon Formulation With Freshly Reconstituted Lyophilized Glucagon Xeris glucagon, Lilly glucagon - Type 1 Diabetes | Phase 2 / Phase 3 | Completed | Steven J. Russell, MD, PhD | 20 | 2014-04-01 | 2019-10-08 |
| D-chiro-Inositol in Overweight Type 1 Diabetes Patients D-chiro-inositol, Folic Acid - Type 1 Diabetes | Phase 3 | Completed | Campus Bio-Medico University | 26 | 2014-03-01 | 2016-04-07 |
| Insulin Clamp Ancillary Study for Assessment of Insulin Resistance Metformin, Placebo - Type 1 Diabetes | Phase 3 | Completed | Jaeb Center for Health Research | 37 | 2014-01-01 | 2017-03-14 |
| Metformin Therapy for Overweight Adolescents With Type 1 Diabetes Metformin (glucophage), oral placebo - Type 1 Diabetes | Phase 3 | Completed | Jaeb Center for Health Research | 164 | 2013-09-01 | 2020-03-03 |
| Initial Testing of the Diabeloop Algorithm in T1D Patients on Pump Therapy Over the Prandial Period and Physical Activity. Insulin - Type 1 Diabetes | Phase 3 | Completed | Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète | 18 | 2013-03-01 | 2014-10-27 |
Showing 20 of 48. Sign in to see all of them.
Diabetes Mellitus, Type 1 (48) · Diabetes Mellitus (9) · Hypoglycemia (6) · Insulin Resistance (6) · Hyperglycemia (2) · Body Weight (1) · Diabetes Mellitus, Type 2 (1) · Diabetic Nephropathies (1) · Health Education (1) · Inflammation (1) · Kidney Diseases (1) · Pain (1) · Peripheral Nervous System Diseases (1)
Autoimmune Diseases (48) · Endocrine System Diseases (48) · Glucose Metabolism Disorders (48) · Immune System Diseases (48) · Metabolic Diseases (48) · Nutritional and Metabolic Diseases (48) · Diabetes Mellitus (39) · Hyperinsulinism (6) · Pathological Conditions, Signs and Symptoms (2) · Signs and Symptoms (2) · Adherence Interventions (1) · Behavior (1) · Diabetes Complications (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1)
Liraglutide (5) · Insulin Glargine (4) · Metformin (3) · Insulin (2) · Insulin Lispro (2) · candesartan cilexetil (2) · pramlintide (2) · Angiotensin-Converting Enzyme Inhibitors (1) · Atorvastatin (1) · Combined Modality Therapy (1) · Continuous Glucose Monitoring (1) · Drug Therapy (1) · Ergocalciferols (1) · Folic Acid (1) · Glucagon (1)
Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète (4) · University at Buffalo (4) · Jaeb Center for Health Research (3) · Andromeda Biotech Ltd. (2) · AstraZeneca (2) · Baylor College of Medicine (2) · Eli Lilly and Company (2) · Medtronic MiniMed, Inc. (2) · University of Colorado, Denver (2) · University of Massachusetts, Worcester (2) · Ain Shams University (1) · Assistance Publique - Hôpitaux de Paris (1) · Benjamin U. Nwosu, MD (1) · Campus Bio-Medico University (1) · Emory University (1)
United States (27) · France (6) · Canada (4) · United Kingdom (4) · Denmark (3) · Germany (3) · Italy (3) · Spain (3) · Australia (2) · China (2) · Czechia (2) · Israel (2) · Poland (2) · Slovakia (2) · South Africa (2)
Ingrid Libman, MD, PhD (2) · Itamar Raz, MD (2) · Kristen Nadeau, MD (2) · Paolo Pozzilli, MD (2) · Paresh Dandona, MBBS, PhD (2) · Rubina Heptulla, MD (2) · Benjamin U Nwosu, MD (1) · Charlene Wong, MD, MS (1)
PMID 18823656, PMID 19451554, PMID 21225239, PMID 21309844, PMID 38682786, PMID 15793249, PMID 18779236, PMID 19429875, PMID 19675193, PMID 19675206, PMID 19821755, PMID 19837791, PMID 20200306, PMID 21266647, PMID 21266648, PMID 21266651, PMID 21299401, PMID 21505208, PMID 22274724, PMID 22416821, PMID 22960587, PMID 23562090, PMID 23579179, PMID 23789889, PMID 23911183, PMID 24163439, PMID 24408401, PMID 24757230, PMID 25392936, PMID 25986629, PMID 26237308, PMID 26246593, PMID 26624824, PMID 27208343, PMID 28039583, PMID 28360027, PMID 28440211, PMID 29059263, PMID 29091568, PMID 29923773, PMID 30566007, PMID 30663187, PMID 30938764, PMID 31696598, PMID 31910885, PMID 32108022, PMID 32438024, PMID 33100044, PMID 33402367, PMID 34174848
2014 (1), R01DK092653 (1), R01DK138366 (1), R01NR004009 (1), R21DK113353 (1), R56DK078645 (1)